Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA GMP Initiative Shifts Warning Letter Review Back To Centers

This article was originally published in The Tan Sheet

Executive Summary

The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of FDA's initiative to create a risk-based approach to pharmaceutical manufacturing
Advertisement

Related Content

Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
Dispute Resolution Pilot Holds Promise Despite Slow Uptake – FDAer
Drug Manufacturing: Industry Urges FDA “For Cause” Preapproval Inspections
GMP Inspections Focus On Cleaning Issues; Warning Letters Trend Downward
GMP Dispute Resolution Pilot Proposed To Evaluate Three-Stage Process
FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record

Topics

Advertisement
UsernamePublicRestriction

Register

PS095160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel